EKF Diagnostics Holdings PLC Change of Adviser (0165C)
June 16 2021 - 2:00AM
UK Regulatory
TIDMEKF
RNS Number : 0165C
EKF Diagnostics Holdings PLC
16 June 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Change of Adviser
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business , announces the appointment of Investec Bank
plc as joint corporate broker, with immediate effect to work
alongside its existing nominated adviser and broker, N+1
Singer.
Julian Baines, CEO of EKF, commented:
"We outlined at our AGM last month a strategy to deliver
significant earnings growth over the next 3 to 4 years and we are
delighted to have the support of both N+1 Singer and Investec as
our joint brokers as we enter into this next phase of accelerated
growth."
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0)29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nominated Adviser & Joint Tel: +44 ( 0)20 7496 3000
Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities in the across sites in the US, UK and
Europe for a variety of life science products. Demand for contract
manufacturing of COVID-19 sample collection tests and kits has
grown dramatically during the pandemic, however the capabilities
can be applied to other areas of diagnostic testing, molecular
disease and forensic test manufacture.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPZZGMVGKZGMZZ
(END) Dow Jones Newswires
June 16, 2021 02:00 ET (06:00 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2024 to May 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From May 2023 to May 2024